---
title: Decision-Making Units in MedTech Sales: Who Actually Buys Your Device?
description: The champion who loves your device is not the person who signs the purchase order. Here is how to map the full decision-making unit for MedTech B2B sales.
authors: Tibor Zechmeister, Felix Lenhard
category: MedTech Startup Strategy & PMF
primary_keyword: decision-making unit MedTech sales
canonical_url: https://zechmeister-solutions.com/en/blog/decision-making-units-medtech-sales
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Decision-Making Units in MedTech Sales: Who Actually Buys Your Device?

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The decision-making unit for a medical device is almost never one person. In a hospital or care-home setting you are selling to at least four roles at once. The clinical champion who uses the device, the influencer or key opinion leader whose word moves others, the budget holder who signs off on the spend, and the procurement function that runs the contract. The champion who loves the device does not sign the purchase order, and the person who signs the purchase order has a completely different pain than the person who uses it. You do not close a MedTech deal until every role in the DMU has its own answer to "why this, why now, why us." Map the DMU before you pitch, and sell to every seat at the table.**

**By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.**

---

## TL;DR

- The decision-making unit (DMU) for a medical device sale is a group, not a person. The clinical champion, the influencer or key opinion leader, the budget holder, and procurement all have to say yes before money moves.
- The champion who uses the device and the person who pays for it are rarely the same human, and their pains are completely different.
- The classic MedTech deal-killer is the "we already pay the staff" objection. The buyer does not save money when your device makes existing salaried workers more efficient, because the salary is already a sunk cost.
- Reimbursement is a second decision-making layer on top of the hospital DMU. A device that nobody gets paid to use does not get used, no matter how good the clinical data looks.
- Public and private hospitals run completely different DMUs. The roles carry the same names. The real levers do not.
- Intended purpose under Article 2(12) of the MDR is the single sentence that tells each DMU role what the device is supposed to do for them. Write it so all four roles see themselves in it.
- Mapping the DMU before you pitch is cheaper than rebuilding the pitch after you lose the first three deals.

---

## A nursing home where the nurses loved the device and the director said no

Tibor watched a MedTech company walk into an Austrian nursing home with a device the care staff actively wanted. The nurses tried it, liked it, asked when they could have more. The device did something real. It saved time on a task the nurses did many times a day. In SaaS terms, this is a dream: the users love it, the users are vocal, the users ask for more. The founder walked out of that building convinced the sale was closed.

The sale was not closed. The sale was not even real.

The nursing home director rejected it in one sentence. "We already pay the nurses." The device made existing salaried staff more efficient. The staff were paid the same whether the device existed or not. The nursing home's cost base did not shift. The founder had built a beautiful efficiency tool for people whose efficiency the buyer was not counting in euros.

The users loved the device. The decision-making unit said no. Those are two different things, and in MedTech, the DMU is the one that matters.

This post is about making sure you never walk into that meeting. The founder above had done one thing wrong. They had mistaken user enthusiasm for a buyer signal. Everything that follows is how to stop doing that.

## The DMU concept, translated into MedTech

Decision-making unit is a B2B sales concept borrowed from industrial and enterprise selling. The core idea is that in any organisation above a certain size, no single person can unilaterally buy anything meaningful. A purchase goes through a set of roles. Users, influencers, budget holders, procurement, compliance. And a deal only closes when every role has its own reason to say yes.

That concept translates directly into MedTech, with two twists that make it harder than a typical enterprise software sale.

The first twist is that the device has a **beneficiary**. The patient. Who is almost never in the room when the decision is made. The patient is the reason the device exists, the lens every regulator applies, and the group whose outcomes determine whether the clinical evidence holds up. But the patient is not a buyer. They do not sit in the procurement meeting. You have to represent their interest in the sale without ever selling to them directly.

The second twist is that the clinical use and the financial logic belong to different people inside the same organisation. The clinician who uses the device experiences its value as time saved, friction removed, or a complication avoided. The hospital that buys the device experiences its value as a line item on a budget. Those two languages have to be translated into each other in the same pitch, in front of the same audience, without losing either.

The DMU concept in MedTech is therefore about mapping every seat at the table, naming the pain each seat feels, and designing a deliberate answer for each one. Not a one-size-fits-all pitch. A DMU map.

## The four typical roles in a MedTech DMU

Most hospital and care-home deals involve some version of four roles. Names and titles vary. The functions are consistent.

**The champion and user.** This is the clinician who actually touches the device. The surgeon in the operating room, the nurse on the ward, the radiologist reading the scan, the care worker in the assisted-living facility. They experience the value of the device as workflow change. They can turn into an internal champion if they like it, which is the single most important signal you can get inside a hospital. They can also kill the device in a hallway conversation if they hate it. They do not, on their own, buy anything.

**The influencer or key opinion leader.** This is the senior clinician whose word carries weight beyond their own use. A head of department, a professor, a medical director, a well-published physician in the relevant sub-speciality. They do not necessarily use the device themselves. Their role is to validate it. To tell other clinicians that this is credible, that the clinical claims hold up, that the approach is sound. An influencer who backs you opens doors. An influencer who stays silent is a tacit no.

**The budget holder.** This is the person with the authority to say yes to the spend. A clinic director, a head of nursing, a managing director, a CFO, or. In larger systems. A value analysis committee that meets once a month and reviews proposals against a framework. The budget holder thinks about the hospital as an economic entity. Cost per case. Throughput per day. Length of stay. Reimbursement codes that cover the device. What gets cut if your device goes in.

**Procurement.** This is the function that runs the contract. Not always a single person. Often a team that handles supplier qualification, legal terms, quality agreements, vendor onboarding, ISO 13485 supplier audits, delivery logistics, and the paperwork of actually placing an order. Procurement will not fight for your device. Procurement will block your device if the terms are messy, if your QMS documentation is incomplete, or if your company does not look like a supplier a hospital can safely onboard. Their role is risk reduction, not enthusiasm.

A deal closes when the champion says "I want this," the influencer says "this is sound," the budget holder says "this makes sense for us," and procurement says "the paperwork is clean." Miss any of the four and the deal stalls or dies.

## Hospital buys, doctor uses, patient benefits. Three languages at one table

The roles above sit inside a simpler truth that every MedTech founder has to internalise. In a hospital deal:

- The hospital is the buyer.
- The doctor (or nurse, or technician) is the user.
- The patient is the beneficiary.

Three different people. Three different languages. Three different definitions of "value."

The hospital speaks in euros, throughput, risk, and reimbursement. "If I buy this, does my cost per case go down? Does my throughput go up? Does it reduce a complication I am currently paying for? Is it reimbursed?"

The doctor speaks in minutes, friction, reliability, and cognitive load. "If I use this, is my day easier or harder? Is it one fewer thing to worry about or one more? Does it save me time in a procedure I already do a hundred times?"

The patient speaks in outcomes. Whether the operation succeeded, whether the pain stopped, whether they went home sooner, whether the side effects were worse or better. They do not speak at the meeting. They are represented by the clinical evidence the company brings and by the clinician's own judgement of what is right for the patient in front of them.

A pitch that only speaks the doctor's language will lose the hospital. A pitch that only speaks the hospital's language will lose the doctor. A pitch that loses the patient. That fails to show real benefit against the clinical question the regulator cares about. Will lose clinical evaluation before it ever reaches a purchase order. The discipline is to speak all three languages in the same conversation, and to speak them to the person in the room who cares about that language.

## The ROI question that kills MedTech deals: "we already pay the nurses"

Go back to the nursing home story. The reason the deal died is a specific ROI failure that first-time MedTech founders walk into again and again.

A device that makes existing salaried staff more efficient does not reduce the buyer's cost base. The salary is fixed. It does not move when the device arrives. What the device actually does is give the staff more headroom in their day. That is a real benefit. But it is a benefit to the staff, not to the budget holder. The budget holder looks at the ledger and sees the same salary number before and after.

For the budget holder to care, the efficiency has to convert into something they do count. Three things tend to work.

**More patients through the same staff.** If the extra headroom lets the facility serve more residents or more procedures without hiring additional staff, that is revenue growth against a fixed cost base. The budget holder counts that.

**Fewer staff for the same patients.** Harder sell in care settings, often politically impossible, but in some contexts. Especially when a facility is already understaffed or paying agency rates. A device that lets them operate with one less full-time equivalent is directly counted.

**Reduced complications, readmissions, or length of stay.** If the efficiency converts into fewer complications, shorter stays, or lower readmission rates, the budget holder counts the avoided downstream cost. This is where most serious MedTech economic arguments live.

The founder in the nursing home story was selling on "your nurses will thank you." The director was buying on "will my salary cost go down, will my resident count go up, or will my complication rate improve." Those two questions did not meet. The device was a good device. The pitch was pointed at the wrong role.

## The reimbursement layer. A second DMU on top of the first

For many MedTech devices, especially anything used in a reimbursed clinical setting, there is a second decision-making unit that sits above the hospital's internal one. That is the reimbursement system.

If a device is not reimbursed. If no insurer, statutory health fund, or national health system pays the hospital for using it. Then every unit the hospital buys comes out of the hospital's own budget. Even a clinically excellent device becomes a hard sell because the hospital is absorbing the full cost against a budget that is already allocated.

If a device is reimbursed. If there is a billing code that the hospital can attach to the use of the device and collect revenue for. Then the economic conversation changes completely. The device is no longer a cost to defend. It is a revenue stream to capture.

The reimbursement system has its own actors. National reimbursement authorities. Statutory insurers. Diagnosis-related group classifications. Local sick funds. The rules differ by country, by region, and sometimes by hospital category. They move slowly. They are opaque. They are where many technically excellent MedTech companies go to die.

The discipline is simple to state and hard to do. **Understand the reimbursement path for your device before you assume the hospital DMU is the only DMU.** If your device requires a new code, or if the existing codes do not cover it properly, you are selling a device the hospital cannot easily fund, and the budget holder's objection will never be about clinical value. It will be about money that does not exist in the budget line.

This is a full topic of its own. It is covered in depth in [MedTech reimbursement strategy](/blog/medtech-reimbursement-strategy) and it belongs on the map from Day 1, not at launch.

## Public and private hospitals run different DMUs

The four roles above exist in both public and private hospitals. What differs is how much weight each role carries and how the decision actually moves.

**Public hospitals** tend to have formal procurement processes, tender requirements, value analysis committees, and strict rules about supplier qualification. The budget holder's authority is constrained by regulation and public-sector procurement law. The champion's influence is real but has to survive a committee. Decisions move slowly. Once they move, they tend to cover multiple sites.

**Private hospitals** often have faster, more personal decision paths. A medical director or managing director can say yes in a meeting. Procurement is lighter. A clinical champion who is also a partner in the practice can sometimes be the whole DMU. Decisions move quickly, but they cover fewer sites at a time.

The consequence for a founder is that the same device sometimes needs two different sales playbooks. One for the public tender process, one for the private relationship sale. Treating a public hospital like a private one ("the chief surgeon loves it, so we are done") is how founders lose tenders to competitors who understood the committee. Treating a private hospital like a public one ("we are waiting for the formal review to start") is how founders burn months on deals that could have closed with a single meeting.

## How to map your device's specific DMU

A DMU map is a concrete artefact, not a concept. For every target buyer, you write down:

- The name and role of the clinical champion or user.
- The name and role of the influencer or key opinion leader whose backing the champion needs.
- The name and role of the budget holder who authorises the spend.
- The procurement contact who will run the contract.
- The reimbursement situation. Is the device reimbursed, under what code, and does the buyer already have the code in their tariff?
- The specific pain each role feels and the specific answer your device provides to that pain, in that role's language.
- The current objection each role would raise if you walked in today.

You do not need all of this in week one. You need it before you commit serious sales effort to the buyer. The cheapest way to build the map is to ask your clinical champion directly. Clinical champions, once they like your device, are usually happy to walk you through their own buying process. Who else has to say yes, what the budget cycle looks like, what procurement will ask for, whether reimbursement is in place. That conversation costs nothing and saves months.

## How to sell to each role in the DMU

Once the map exists, the pitch stops being one pitch and becomes four.

**To the champion,** you sell workflow and reliability. Time per case. Friction removed. Cognitive load. Whether the device fits the other fourteen things they do in a shift. You give them the tools to explain the device to colleagues in their own language.

**To the influencer,** you sell clinical credibility. Evidence quality. Peer acceptance. Fit with guidelines. Whether the device holds up under the scrutiny of a head of department who does not want to be embarrassed in front of colleagues. You bring them the clinical evidence and you respect their time.

**To the budget holder,** you sell economics. Cost per case, revenue per case, throughput, reimbursement capture, avoided complication cost, staff efficiency that converts into a number on a ledger. You bring a model with real numbers, not marketing slides, and you show the break-even point.

**To procurement,** you sell operational safety. A clean QMS. ISO 13485 certification where applicable. A quality agreement template they can actually sign. Vendor documentation that does not create work for them. Delivery logistics that do not disrupt the ward. The absence of drama.

Four pitches. Same device. Same founder. Same meeting if you have to. Different answers for each seat at the table.

## Common DMU mistakes

- **Mistaking champion enthusiasm for a closed deal.** The champion loves it. The champion does not sign the purchase order. Until you have heard "yes" from the budget holder and "paperwork is clean" from procurement, you do not have a deal.
- **Selling the doctor's benefit to the budget holder.** Time saved for a salaried clinician is not automatically a cost saving for the hospital. Translate it into something the budget holder counts or accept that you do not have an economic argument yet.
- **Ignoring reimbursement until launch.** Discovering at launch that there is no billing code for your device is a preventable disaster. Map the reimbursement path alongside the DMU map.
- **Running one pitch for all four roles.** The same deck cannot speak to a champion, an influencer, a budget holder, and procurement. Build four variants of the pitch and use the right one in the right conversation.
- **Treating a public hospital like a private one.** Public procurement is a process. Personal charm is not a substitute for a winning tender submission.
- **Assuming procurement will not block the deal.** Procurement does not fight for your device. If your vendor paperwork is sloppy, procurement will quietly put the file at the bottom of the pile.

## The Subtract to Ship angle on DMU

Every activity a MedTech startup runs should trace back to either an MDR requirement or a DMU role. If it cannot be traced to either, it is drag.

Subtract to Ship applied to MedTech sales is a short list.

- Every conversation in phase one should be with a specific, named person in a specific DMU role. "The hospital market" is not a role. "The head of nursing at a 180-bed geriatric facility in Styria" is.
- Every slide in your pitch should be aimed at a named role. If a slide does not answer a specific pain for a specific role, it is there for you, not for the buyer, and it should be cut.
- Every claim about the device's benefit should be written in the language of the role who has to care about that benefit. Time saved belongs in the clinician's section. Cost saved belongs in the budget holder's section. Mixing them is how you confuse both audiences at once.
- Every intended purpose sentence under Article 2(12) of the MDR should be defensible in front of all four DMU roles and a Notified Body auditor. (Regulation (EU) 2017/745, Article 2, paragraph 12.) If it only speaks the clinician's language, classification and the budget argument will drift apart later.
- Every assumption about who buys your device should be tied back to the patient the regulator cares about. Article 2(1) of the MDR anchors the device to a medical purpose for an identifiable user population. (Regulation (EU) 2017/745, Article 2, paragraph 1.) The buyer has to fund that purpose. If the buyer's economics and the patient's benefit do not line up, you have a DMU problem and a regulatory problem at once.

Read [the Subtract to Ship framework for MDR](/blog/subtract-to-ship-framework-mdr) for the same discipline applied across the whole certification project.

## Reality Check. Where do you stand on your DMU?

Answer these honestly. If more than two are weak, your DMU map is not good enough to start serious sales work.

1. Can you name, by role, the four people in a typical target buyer who have to say yes before a purchase order is signed?
2. Have you spoken directly to someone in each of those four roles. Champion, influencer, budget holder, procurement. About your device, or only to the champion?
3. Do you know the specific pain the budget holder feels that your device answers, in the budget holder's own language, with a number?
4. Is your device's benefit something that converts into an amount the budget holder counts. Reduced cost, added revenue, avoided complication. Or is it currently only "nurses will thank you"?
5. Do you know whether the device is reimbursed in your target geography, under which code, and whether your target buyers already have that code active in their tariff?
6. Do you know whether your target buyers are public or private, and do you have a different sales motion for each?
7. Have you heard a procurement contact tell you what they will need from your QMS and your vendor paperwork before they can onboard you?
8. If your lead clinical champion left their job tomorrow, would the deal still be alive, or would it die with them?

## Frequently Asked Questions

**Who is the real buyer of a medical device. The doctor or the hospital?**
The hospital is the legal and financial buyer. A doctor, no matter how senior, almost never has unilateral authority to purchase a device for the facility. The doctor's role in the decision-making unit is as champion and user. They can push the deal forward and they can kill it, but they do not sign the purchase order. In care-home settings the equivalent role is the director or managing director. Treat the doctor as the most important influencer inside the DMU and the hospital as the buyer.

**What is a decision-making unit in MedTech sales?**
A decision-making unit is the group of people inside a hospital, clinic, or care home who collectively decide whether a device gets purchased. In MedTech it typically includes four roles. A clinical champion or user, an influencer or key opinion leader, a budget holder, and procurement. A deal closes when every role has its own reason to say yes. Selling to only one role, even an enthusiastic one, is the most common reason early MedTech deals stall.

**Why did a nursing home reject a device the nurses loved?**
Because the device made existing salaried nurses more efficient without changing the nursing home's cost base. The nurses were paid the same whether the device was there or not, so the budget holder saw no economic benefit. This is the classic "we already pay the staff" objection, and it kills MedTech deals that sell user benefit without translating it into a buyer benefit in euros.

**How do you sell to hospital procurement without losing the clinical champion?**
Build two variants of the same pitch. The clinical pitch sells workflow, reliability, and clinical evidence. The procurement pitch sells QMS maturity, ISO 13485 compliance where applicable, clean vendor paperwork, and predictable delivery. Run both in parallel. The clinical champion does the internal work of moving the deal; your job is to make sure procurement never has a reason to block it.

**Is reimbursement part of the decision-making unit?**
Yes, indirectly. Reimbursement sits above the hospital's internal DMU as an external constraint. If a device is reimbursed, the budget holder can treat it as revenue capture rather than cost absorption. If it is not reimbursed, the budget holder has to defend it as pure spend, which is a much harder sell. Mapping reimbursement is part of mapping the DMU for any device used in a reimbursed clinical setting.

**Does the DMU concept work for private clinics and solo practices?**
It still applies, but the roles collapse. In a solo practice the clinician, the budget holder, and procurement can all be the same person, and the deal can close in a single conversation. In a small private clinic the medical director is often both champion and budget holder, with a practice manager running procurement. The principle. Every role has to say yes. Holds even when one human plays several roles. The difference is that you can address several roles at once instead of in separate meetings.

## Related reading

- [The No-Bullshit Guide to MDR Compliance for First-Time Founders](/blog/no-bullshit-mdr-guide-first-time-founders) – the direct orientation post on what MDR actually asks of a startup.
- [The Subtract to Ship Framework for MDR](/blog/subtract-to-ship-framework-mdr) – the methodology this post applies to sales.
- [Product-Market Fit for MedTech Startups](/blog/product-market-fit-medtech-startups) – the hub post that frames PMF against the MedTech DMU.
- [The MedTech Startup Paradox](/blog/medtech-startup-paradox) – why the speed-to-market assumptions founders arrive with do not match the MedTech reality.
- [How to Validate a MedTech Idea Before MDR](/blog/validate-medtech-idea-before-mdr) – the phase-one validation tools that feed a DMU map.
- [Wellness First, Medical Device Later](/blog/wellness-first-medical-device-later) – how the two-step market entry interacts with the DMU.
- [The Champion vs the Decision Maker in Hospital Sales](/blog/champion-vs-decision-maker-hospital-sales) – the deeper dive on the role-split that kills first-time deals.
- [Selling to Hospital Procurement](/blog/selling-hospital-procurement) – the operational rules for working with procurement teams.
- [Key Opinion Leaders in MedTech](/blog/key-opinion-leaders-medtech) – how to identify, approach, and work with influencers.
- [Public vs Private Hospital Sales in MedTech](/blog/public-private-hospital-sales-medtech) – the two sales motions, compared side by side.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, consolidated text. Articles cited: Article 2(1) definition of medical device; Article 2(12) intended purpose. Official Journal L 117, 5.5.2017.
2. Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices. Official Journal L 80, 20.3.2023.

---

*This post is part of the MedTech Startup Strategy and PMF series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The champion who loves your device is not the person who signs the purchase order. Map the full DMU before you pitch, or pay for the lesson in lost deals.*

---

*This post is part of the [MedTech Startup Strategy & PMF](https://zechmeister-solutions.com/en/blog/category/startup-strategy) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*